Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Ritchie

Showing results (371-380 of 395) with videos related to

Pageof 40
Sort By:
Trials|July 26, 2022
The APPLE Tree programme: Active Prevention in People at risk of dementia through Lifestyle, bEhaviour change and Technology to build REsiliEnce-randomised controlled trialM Poppe, L Duffy, N L Marchant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2022
Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and EfficacyClaire N Harrison, Jacqueline S Garcia, Tim C P Somervaille, et al.
Blood Advances|October 22, 2020
Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and responseOk-Kyong Chaekal, Andromachi Scaradavou, Emeline Masson Frenet, et al.
NEJM Evidence|August 26, 2025
Pemigatinib for Myeloid/Lymphoid Neoplasms with <i>FGFR1</i> RearrangementSrdan Verstovsek, Jean-Jacques Kiladjian, Alessandro M Vannucchi, et al.
Cancer|December 7, 2017
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemiaGail J Roboz, Hagop M Kantarjian, Karen W L Yee, et al.
Leukemia & Lymphoma|January 8, 2015
Phase I dose escalation study of lestaurtinib in patients with myelofibrosisElizabeth O Hexner, John Mascarenhas, Josef Prchal, et al.
Journal of Internal Medicine|August 25, 2004
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive ImpairmentB Winblad, K Palmer, M Kivipelto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2018
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid LeukemiaJeffrey E Lancet, Geoffrey L Uy, Jorge E Cortes, et al.
Sleep Health|September 30, 2023
Distribution of dim light melatonin offset (DLMOff) and phase relationship to waketime in healthy adults and associations with chronotypeRebecca C Cox, Alivia B Blumenstein, Tina M Burke, et al.
BMC Cancer|April 4, 2018
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemiaEhab Atallah, Charles A Schiffer, Kevin P Weinfurt, et al.
Pageof 40

Showing results (371-380 of 395) with videos related to

Sort By:
Pageof 40
Trials|July 26, 2022
The APPLE Tree programme: Active Prevention in People at risk of dementia through Lifestyle, bEhaviour change and Technology to build REsiliEnce-randomised controlled trialM Poppe, L Duffy, N L Marchant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2022
Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and EfficacyClaire N Harrison, Jacqueline S Garcia, Tim C P Somervaille, et al.
Blood Advances|October 22, 2020
Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and responseOk-Kyong Chaekal, Andromachi Scaradavou, Emeline Masson Frenet, et al.
NEJM Evidence|August 26, 2025
Pemigatinib for Myeloid/Lymphoid Neoplasms with <i>FGFR1</i> RearrangementSrdan Verstovsek, Jean-Jacques Kiladjian, Alessandro M Vannucchi, et al.
Cancer|December 7, 2017
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemiaGail J Roboz, Hagop M Kantarjian, Karen W L Yee, et al.
Leukemia & Lymphoma|January 8, 2015
Phase I dose escalation study of lestaurtinib in patients with myelofibrosisElizabeth O Hexner, John Mascarenhas, Josef Prchal, et al.
Journal of Internal Medicine|August 25, 2004
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive ImpairmentB Winblad, K Palmer, M Kivipelto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2018
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid LeukemiaJeffrey E Lancet, Geoffrey L Uy, Jorge E Cortes, et al.
Sleep Health|September 30, 2023
Distribution of dim light melatonin offset (DLMOff) and phase relationship to waketime in healthy adults and associations with chronotypeRebecca C Cox, Alivia B Blumenstein, Tina M Burke, et al.
BMC Cancer|April 4, 2018
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemiaEhab Atallah, Charles A Schiffer, Kevin P Weinfurt, et al.
Pageof 40